Gavin is a neuropharmacologist with deep expertise in peptide signaling, brain circuitry, and translational neuroscience in ageing, mental health, and neuropsychiatric disorders. He is Associate Professor and Head of the Department of Pharmacology at the Yong Loo Lin School of Medicine, National University of Singapore (NUS). He is also a principal investigator affiliated with the Neurobiology Programme at the Life Sciences Institute and the Healthy Longevity and Precision Medicine Translational Research Programmes at NUS.

Gavin earned his PhD in Pharmacology from the Institute of Psychiatry at King’s College London, where he also completed postdoctoral research. He subsequently held roles in the biotechnology and pharmaceutical industry at ReNeuron Limited and Eli Lilly and Company before joining NUS. His laboratory focuses on peptide neuropharmacology using a broad translational toolkit that includes systems neurobiology, behavioral neuroscience, electrophysiology, and optogenetics. 

His contributions to the field have been recognized with several awards, including the Asian College of Neuropsychopharmacology Basic Scientist Award, the Singapore Neuroscience Association Distinguished Neuroscientist Award, and the GlaxoSmithKline Academic Centre of Excellence Research Award. Gavin also directs the NUS Neuroscience and Metabolic Phenotyping Core, which provides behavioral and metabolic phenotyping capabilities to the broader research community. In addition, he holds a Master’s degree in Medical and Health Professions Education from Eastern Virginia Medical School. Under his leadership as the Head of the Department of Pharmacology, the National University of Singapore is currently ranked 8th in the QS World University Rankings by Subject 2025 for Pharmacy and Pharmacology and 9th in the U.S. News Best Global Universities for Pharmacology and Toxicology. 

At NeuraClick, Gavin provides scientific leadership across neuropharmacology, translational neuroscience, and preclinical strategy, helping guide the development of the company’s macrocyclic peptide therapeutics for CNS and neuro-metabolic disorders.